• Home
  • Guidelines
  • Portfolio
  • Partners
  • Team
  • News
  • Contact

  • Vestaron Closes Another $10M in Series C Funding to Fuel Product Development and Market Expansion

    https://www.vestaron.com/vestaron-closes-another-10m-in-series-c-funding-to-fuel-product-development-and-market-expansion/

    Bernadette Ballard-Reid

    November 29, 2022
    Uncategorized

  • SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting

    https://investors.seastarmedical.com/news/news-details/2022/SeaStar-Medicals-Lead-Product-Candidate-the-Selective-Cytopheretic-Device-SCD-Included-in-Consensus-Statement-for-Pediatric-Acute-Kidney-Injury-in-First-Pediatric-Acute-Disease-Quality-Initiative-ADQI-Meeting/default.aspx

    Bernadette Ballard-Reid

    November 29, 2022
    Uncategorized

  • HAPPE Spine Announces Close Of $3.35 Million Round In Series A Investment

    https://happeortho.com/series-a-investment/

    Bernadette Ballard-Reid

    November 29, 2022
    Uncategorized

  • HAPPE Spine Announces Additional Patents for Hydroxyapatite Porous PolyEtheretherketone Devices

    https://happeortho.com/additional-patents/

    Bernadette Ballard-Reid

    November 29, 2022
    Uncategorized

  • GreenMark Recognized as a 2021 Best of Class Technology Award Winner

    https://greenmark.bio/wp-content/uploads/GreenMark-Cellerant-2021-BOC-Award-090821.pdf

    Bernadette Ballard-Reid

    November 29, 2022
    Uncategorized

  • GreenMark-LumiCare FDA Clearance

    https://greenmark.bio/wp-content/uploads/GreenMark-LumiCare-FDA-Clearance-040821.pdf

    Bernadette Ballard-Reid

    November 29, 2022
    Uncategorized

  • Shoulder Innovations Announces Close of $2.5 Million Round in Series A

    Shoulder Innovations Announces Close Of $2.5 Million Round In Series Ahttps://shoulderinnovations.com/series-a-investment/

    Bernadette Ballard-Reid

    January 19, 2021
    Uncategorized

  • GreenMark Biomedical Secures Follow-on Investment

    GreenMark-Follow-On-Investment-082420.pdfhttps://greenmark.bio/wp-content/uploads/GreenMark-Follow-On-Investment-082420.pdf

    Bernadette Ballard-Reid

    January 19, 2021
    Uncategorized

  • ONL Therapeutics Closes $46.9 Million in Series B Financing

    ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications – ONL Therapeutics

    Bernadette Ballard-Reid

    January 19, 2021
    Uncategorized

  • ‘TREMENDOUS WIN:’ Tetra Therapeutics’ sale offers healthy returns for investors, validation for local ecosystem

    https://mibiz.com/sections/finance/tremendous-win-tetra-therapeutics-sale-offers-healthy-returns-for-investors-validation-for-local-ecosystem

    Bernadette Ballard-Reid

    January 19, 2021
    Uncategorized
  • ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human
    Clinical Study  https://www.onltherapeutics.com

     

     

    Bernadette Ballard-Reid

    September 11, 2019
    Uncategorized

  • GreenMark Secures Additional Funding for Cavity Identification and Treatment http://greenmark.bio/wp-content/uploads/GreenMark-Additional-Funding-031919.pdf

    Bernadette Ballard-Reid

    March 20, 2019
    Uncategorized

  • New Website

    Welcome to the Biosciences Research & Commercialization Center’s new website!

    Michael Sisk

    February 25, 2019
    Uncategorized
Previous Page
1 2

© 2006 Biosciences Research & Commercialization Center of Western Michigan University Research Foundation, all rights reserved.